A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists
- 15 February 2013
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (4) , 1063-1069
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Chemokine Signaling and the Management of Neuropathic PainMolecular Interventions, 2009
- Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin ResistanceJournal of Biological Chemistry, 2006
- MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesityJournal of Clinical Investigation, 2006
- CCR2 modulates inflammatory and metabolic effects of high-fat feedingJournal of Clinical Investigation, 2006
- Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune EncephalomyelitisJournal of Experimental Medicine, 2001
- Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2)Journal of Experimental Medicine, 2000
- Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune EncephalomyelitisJournal of Experimental Medicine, 2000
- Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient miceAtherosclerosis, 1999
- An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse ModelJournal of Experimental Medicine, 1997
- THE ROLE OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) IN THE PATHOGENESIS OF COLLAGEN-INDUCED ARTHRITIS IN RATSThe Journal of Pathology, 1997